Type Whole antibody ATC code none ChemSpider none | Source Human CAS Number 1245634-25-6 | |
Target Clostridium difficile toxin A | ||
Actoxumab is a human monoclonal antibody designed for the prevention of recurrence of Clostridium difficile infection.
This drug, along with bezlotoxumab, was developed through Phase II efficacy trials by a partnership between Medarex Inc and MassBiologics of the University of Massachusetts Medical School. The project was then licensed to Merck & Co., Inc. for further development and commercialization.
A study compared it with bezlotoxumab (that targets CD toxin-B) and found Actoxumab less effective.
References
Actoxumab Wikipedia(Text) CC BY-SA